Biotech Stocks Growth Stocks Healthcare Stocks Life Sciences Mid Cap Stocks Small Caps Stocks

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the…

ByNick Sundich

01

Apr 2026

Basic Materials Biotech Stocks Blue Chip Stocks Defence Stocks Education Education Stocks Financials Large Caps Mid Cap Stocks Mining Stocks Oil and Gas Stocks Property Resources Safe Stocks Semiconductor stocks Small Caps Stocks Tech Stocks Technology

Here are 7 ASX 200 Stocks Winning During The Iran War…And Aren’t In The Soaring Oil and Gas Space!

Investors asked to name ASX 200 stocks winning during the Iran war would likely think of oil and gas stocks, benefiting from soaring prices. This is not incorrect - oil…

ByNick Sundich

30

Mar 2026

Healthcare Stocks

The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

4 ASX Healthcare Stocks to Buy at Valuation Lows ASX healthcare stocks have had a brutal run. Five years of underperformance, persistent earnings downgrades, and aggressive rate hikes have pushed…

ByUjjwal Maheshwari

16

Mar 2026

Healthcare Stocks Tech Stocks

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Pixclara Back With the FDA Telix has resubmitted its NDA to the FDA for Pixclala, its PET imaging agent for recurrent or progressive glioma, a common type of brain tumour. Pixclara…

ByCharlie Youlden

16

Mar 2026

Biotech Stocks Healthcare Stocks Life Sciences

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent…

ByNick Sundich

20

Jan 2026

Tech Stocks Technology

Telix Pharmaceuticals (ASX:TLX) China Regulatory Progress Emerges After a 55% Sell-Off

The China Regulatory Path Is Still Moving Forward Telix Pharmaceuticals (ASX:TLX) has had a challenging start to the year, with the share price down around 55% and now trading near…

ByCharlie Youlden

13

Jan 2026

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

The Market Lost Patience, the Strategy Did Not Telix Pharmaceuticals (ASX:TLX) is one of the more compelling examples of a biotech company pushing through the commercialisation chasm, often the most…

ByCharlie Youlden

22

Dec 2025

Healthcare Stocks Tech Stocks Technology

Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?

Why Telix Pharmaceuticals Pullback Could Be a Second Chance Telix Pharmaceuticals (ASX:TLX) has faced a challenging year, particularly for a company that previously delivered consistently strong growth. Disclosure issues and…

ByCharlie Youlden

21

Oct 2025

Healthcare Stocks

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech…

ByNick Sundich

15

Oct 2025

Healthcare Stocks Technology

Telix Pharmaceuticals (ASX: TLX) Stages a Comeback as FY25 Update Signals Renewed Momentum

Telix Pharmaceuticals (ASX: TLX) has been one of Australia’s most talked-about biotech stories ... a company that once soared on excitement, stumbled through FDA delays and accounting scrutiny, and is…

ByCharlie Youlden

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

Here are 7 ASX 200 Stocks Winning During The Iran War…And Aren’t In The Soaring Oil and Gas Space!

The 4 Best ASX Healthcare Stocks to Buy as the Sector Trades at Two-Decade Valuation Lows

Telix (ASX:TLX) Pixclara NDA Resubmitted, The FDA Clock Restarts

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Telix Pharmaceuticals (ASX:TLX) China Regulatory Progress Emerges After a 55% Sell-Off

Telix Pharmaceuticals (ASX:TLX) Through the Commercialisation Chasm

Is Telix Pharmaceuticals (ASX:TLX) Now Undervalued With Phase 3 China Clinical Success?

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

Telix Pharmaceuticals (ASX: TLX) Stages a Comeback as FY25 Update Signals Renewed Momentum

PLS Group (ASX:PLS) Hits Record High on...

Narryer Metals (ASX:NYM) Tim Goyder Back...

Sovereign Metals (ASX:SVM) DFS lands,$2....

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here